Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial-Reference-Cited by-同舟云学术

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial

Published:2018-05 Issue:5 Volume:33 Page:829-842.e5
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Mackay Alan,Burford Anna,Molinari Valeria,Jones David T.W.,Izquierdo Elisa,Brouwer-Visser Jurriaan,Giangaspero Felice,Haberler Christine,Pietsch Torsten,Jacques Thomas S.,Figarella-Branger Dominique,Rodriguez Daniel,Morgan Paul S.,Raman Pichai,Waanders Angela J.,Resnick Adam C.,Massimino Maura,Garrè Maria Luisa,Smith Helen,Capper David,Pfister Stefan M.,Würdinger Thomas,Tam Rachel,Garcia Josep,Thakur Meghna Das,Vassal Gilles,Grill Jacques,Jaspan Tim,Varlet Pascale,Jones Chris

Funder

F. Hoffmann-La Roche Ltd

NIHR Biomedical Research Center

ICR

Associazione per la Ricerca sui Tumori Cerebrali del Bambino

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference57 articles.

1. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas;Bautista;Pediatr. Blood Cancer,2014

2. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors;Benesch;Ann. Oncol.,2008